<DOC>
	<DOCNO>NCT01367613</DOCNO>
	<brief_summary>This 3 month open-label extension study allow patient complete Protocol MNTX 302 receive SC MNTX .</brief_summary>
	<brief_title>Open-Label Treatment Extension Protocol MNTX 302</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Must enrol consent within 28 day end study visit MNTX 302 14 day first dose study drug MNTX 302 . 2 . Negative pregnancy test 3 . Stable vital sign 1 . Women pregnant and/or nursing 2 . Received investigational product , MNTX , past 30 day 3 . Evidence fecal impaction 4 . Clinically significant active diverticular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Advanced medical illness</keyword>
</DOC>